Gastrectomy Clinical Trials

Clinical trials related to Gastrectomy Procedure

Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

Proximal gastric and esophagogastric junction cancers comprise up to 40% of gastric malignancies. For localized disease, proximal gastrectomy is the main radical procedure, but reconstruction of GI tract often leads to significant functional issues. Rising use of proximal resections and broader indications have increased attention to postoperative quality of life (QoL). Common reconstructions include direct esophagogastrostomy (various types), double-tract reconstruction, jejunal interposition, and newer anti-reflux anastomoses (e.g., double-flap, overlap, tunnel techniques). Each method has unique pros and cons regarding reflux esophagitis, food passage, dumping syndrome, nutritional changes, and long-term QoL. No consensus exists on the optimal technique, leading to variable practices and outcomes. Most research focuses on oncologic radicality and survival, while functional results and QoL remain understudied. Systematic evaluation of functional outcomes across reconstruction types after proximal subtotal gastrectomy is needed in Russian Federation to improve QoL, advance research, and standardize treatment of proximal gastric and EGJ cancers.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• All consecutive patients with clinically documented primary Gastric or Esophagogastric Junction malignancy (including Siewert I and II) undergoing proximal gastrectomy with curative intent - via open, laparoscopic or robotic approach between 01th January 2025 and 31th December 2026

Locations
Other Locations
Russian Federation
P.Herzen Moscow Oncological Research Institute
RECRUITING
Moscow
Contact Information
Primary
Andrey Ryabov, MD, PhD
ryabovdoc@mail.ru
+7 (495) 150-11-22
Time Frame
Start Date: 2025-01-01
Estimated Completion Date: 2028-06-01
Participants
Target number of participants: 300
Treatments
Patients with morbidity and mortality
Patients who suffered from any type of morbidity after surgery
Patients without morbidity and mortality
Patients who did not suffered from any type of morbidity after surgery
Sponsors
Collaborators: A.Loginov Moscow Clinical Scientific Center
Leads: P. Herzen Moscow Oncology Research Institute

This content was sourced from clinicaltrials.gov